Michael Aberman

Michael Aberman, M.D. is a biotechnology executive with over 20-years experience who is on the board or advising several early stage biotechnology companies. Previously, he was the president and chief executive officer of Quentis Therapeutics, an early stage biotech company. Prior to joining Quentis, Dr. Aberman spent over seven years at Regeneron Pharmaceuticals as the Senior Vice President ofInvestor Relations and Strategy. In that role, Dr. Aberman was a member of the senior management team and was responsible for the investor relations, corporate communications, business development, and corporate strategy functions at Regeneron. Prior to joining Regeneron, Dr. Aberman spent six years as a Wall Street research analyst covering the biotechnology industry at Credit Suisse and Morgan Stanley. Before moving to Wall Street, Dr. Abermanwas Director of Business Development at Antigenics, Inc., an oncology-focused biotechnology company. Dr. Aberman received B.A. from Cornell University (’93),his medical degree from the University of Toronto (’97), completed residency training at New York Presbyterian Hospital, and received an M.B.A. from TheWharton School of Business (’01).